Biosimilar Development News
-
Prestige Biopharma And Pharmapark Announce License And Supply Agreement To Commercialize Prestige's Bevacizumab Biosimilar In The Russian Federation
4/15/2021
Prestige BioPharma and Pharmapark LLC today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma's Bevacizumab biosimilar in the Russian Federation.
-
Xcenda’s FormularyDecisions Launches Resource Hub For Biosimilar Products
4/8/2021
As the demand for biosimilar product information continues to grow among payers, Xcenda’s FormularyDecisions—a secure online platform that facilitates information exchange between manufacturers and healthcare decision-makers—announced today the launch of a Biosimilars Hub.
-
Biogen And Bio-Thera Solutions Announce Commercialization And License Agreement For Proposed Biosimilar Currently In Phase 3 With The Potential To Treat Moderate To Severe Rheumatoid Arthritis
4/8/2021
Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 (IL-6) receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA®1 (tocilizumab).
-
PlantForm Signs Agreement With Bio-Manguinhos/Fiocruz To Develop A Biosimilar Pembrolizumab Cancer Drug
4/6/2021
PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) today announced a collaborative research and development agreement to develop a biosimilar pembrolizumab for the Brazilian market.
-
Value Of Biosimilars In Women’s Health: HealthyWomen Roundtable Series Roundup
4/5/2021
HealthyWomen, a leader in women’s health education, brought together patient groups, physicians, and industry leaders to discuss how critical biosimilars are to women’s health and how these lower-cost drugs can expand access to life-saving treatments through a series of webinars.
-
European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer
4/1/2021
The European Commission (EC) has approved mAbxience's MB02 biosimilar to Avastin® (Bevacizumab), in Europe.
-
STADA Strengthens Oncology Offering By Launching Bevacizumab Biosimilar
3/30/2021
STADA has broadened its specialty oncology portfolio by introducing biosimilar bevacizumab upon receiving a pan-European marketing authorisation.
-
Making Most Out Of Launched Products, Fueling Diversified Innovation Through Integrated Platform
3/29/2021
Henlius (2696.HK) announced the financial results for the year ended 31 December 2020. 2020 marked a meaningful year for Henlius as the Company gathered the pace in commercialization and continued the momentum for innovation.
-
Samsung Bioepis Continues Global Market Expansion With Launch Of HADLIMA™ In Australia And Canada In Partnership With Merck & Co.
3/29/2021
Samsung Bioepis Co., Ltd. today announced its expansion of its global footprint to Australia with the launch of HADLIMA™ i (adalimumab), a biosimilar referencing HUMIRA ii(adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa and plaque psoriasis.
-
Alvotech Disputes Abbvie’s Allegations Of Wrongdoing
3/25/2021
Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab). Alvotech will vigorously defend against these allegations.